Otezla has an established safety profile with no initial or ongoing lab monitoring ¹

PALACE 1-3: ADVERSE REACTIONS THROUGH WEEK 16

AN ESTABLISHED SAFETY PROFILE THROUGH WEEK 16 ¹

PALACE 1-3: Adverse reactions reported in ≥2% of patients on Otezla 30 mg
BID and ≥1% observed in patients on placebo for up to day 112 (week 16) ^1,*

Table of PALACE 1-3 adverse reactions in Otezla patients through Week 16

*After initial 5-day titration. ^†Of the reported gastrointestinal adverse reactions, 1 patient experienced a serious adverse reaction of nausea and vomiting on Otezla 30 mg BID; 1 patient treated with Otezla 20 mg BID experienced a serious adverse reaction of diarrhea. ^‡Of the reported adverse drug reactions, none were serious.

Discontinuation rates due to adverse reactions in the 3 trials ¹:

Otezla arm, 4.6%; placebo arm, 1.2%
Less than 2% of patients discontinued Otezla due to nausea, diarrhea, or headache

5-Year Safety Data Video

WATCH VIDEO

THE MAJORITY OF PATIENTS REPORTING THE MOST COMMON ADVERSE REACTIONS OCCURRED WITHIN THE FIRST
2 WEEKS OF TREATMENT AND TENDED TO RESOLVE OVER TIME WITH CONTINUED DOSING ¹

Postmarketing reports of severe diarrhea, nausea, and vomiting have been associated with the use of Otezla. In some cases patients were hospitalized. Monitor patients who are more susceptible to complications of diarrhea or vomiting ¹

PALACE 4: ADVERSE REACTIONS THROUGH WEEK 16

AN ESTABLISHED SAFETY PROFILE IN
DMARD-NAÏVE PATIENTS THROUGH WEEK 16 ²

PALACE 4: Adverse reactions reported in ≥ 5% of patients through week 16 ^2,§

Table of PALACE 4 adverse reactions in Otezla patients through Week 16

^§Before early escape.

Thumbnail image for video about the PALACE 4 clinical trial data in Psoriatic Arthritis DMARD-naïve patients

PALACE 4 Data Video

WATCH VIDEO

BID, twice daily; DMARD, disease-modifying antirheumatic drug; TEAE, treatment-emergent adverse event.

Safety Overview

Adverse Reactions
Through 5 Years

IMPORTANT SAFETY INFORMATION

Contraindications

Otezla/OTEZLA XR is contraindicated in patients with a known hypersensitivity to apremilast or to any of the excipients in the formulation

Warnings and Precautions

Hypersensitivity: Hypersensitivity reactions, including angioedema and anaphylaxis, have been reported during postmarketing surveillance. If signs or symptoms of serious hypersensitivity reactions occur, discontinue Otezla/OTEZLA XR and institute appropriate therapy

IMPORTANT SAFETY INFORMATION

Contraindications

Otezla/Otezla XR is contraindicated in patients with a known hypersensitivity to apremilast or to any of the excipients in
the formulation

Warnings and Precautions

Hypersensitivity: Hypersensitivity reactions, including angioedema and anaphylaxis, have been reported during
postmarketing surveillance. If signs or symptoms of serious hypersensitivity reactions occur, discontinue Otezla/Otezla
XR and institute appropriate therapy
Diarrhea, Nausea, and Vomiting: Cases of severe diarrhea, nausea, and vomiting were associated with the use of Otezla.
Most events occurred within the first few weeks of treatment. In some cases, patients were hospitalized. Patients 65
years of age or older and patients taking medications that can lead to volume depletion or hypotension may be at a
higher risk of complications from severe diarrhea, nausea, or vomiting. Monitor patients who are more susceptible to
complications of diarrhea or vomiting; advise patients to contact their healthcare provider. Consider Otezla/Otezla XR
dose reduction or suspension if patients develop severe diarrhea, nausea, or vomiting
Depression: Carefully weigh the risks and benefits of treatment with Otezla/Otezla XR for patients with a history of depression and/or suicidal thoughts/behavior, or in patients who develop such symptoms while on Otezla/Otezla XR. Patients, caregivers, and families should be advised of the need to be alert for the emergence or worsening of depression, suicidal thoughts or other mood changes, and they should contact their healthcare provider if such changes occur
- Plaque Psoriasis: Treatment with Otezla is associated with an increase in depression. During clinical trials in adult patients with moderate to severe plaque psoriasis, 1.3% (12/920) of patients reported depression compared to 0.4% (2/506) on placebo. Depression was reported as serious in 0.1% (1/1308) of patients exposed to Otezla, compared to none in placebo-treated patients (0/506). Suicidal behavior was observed in 0.1% (1/1308) of patients on Otezla, compared to 0.2% (1/506) on placebo. One patient treated with Otezla attempted suicide; one patient on placebo committed suicide
- Psoriatic Arthritis: Treatment with Otezla is associated with an increase in depression. During clinical trials in adult patients, 1.0% (10/998) reported depression or depressed mood compared to 0.8% (4/495) treated with placebo. Suicidal ideation and behavior was observed in 0.2% (3/1441) of patients on Otezla, compared to none in placebo-treated patients. Depression was reported as serious in 0.2% (3/1441) of patients exposed to Otezla, compared to none in placebo-treated patients (0/495). Two patients who received placebo committed suicide compared to none on Otezla
- Behçet’s Disease: Treatment with Otezla is associated with an increase in depression. During the clinical trial, 1% (1/104) reported depression or depressed mood compared to 1% (1/103) treated with placebo. No instances of suicidal ideation or behavior were reported in patients treated with Otezla or treated with placebo
Weight Decrease: Monitor body weight regularly; evaluate unexplained or clinically significant weight loss, and consider discontinuation of Otezla/Otezla XR
- Plaque Psoriasis: Body weight loss of 5-10% occurred in 12% (96/784) of adult patients with moderate to severe plaque psoriasis treated with Otezla and in 5% (19/382) of patients treated with placebo. Body weight loss of ≥10% occurred in 2% (16/784) of adult patients treated with Otezla compared to 1% (3/382) of patients treated with placebo. Body weight loss of 5%-10% occurred in 12% (19/163) of pediatric patients with moderate to severe plaque psoriasis treated with Otezla compared to 2.5% (2/80) with placebo. Body weight loss of ≥10% occurred in 1% (1/163) of pediatric patients treated with Otezla twice daily compared to 0% (0/80) of patients with placebo. Closely monitor growth (height and weight) in Otezla/Otezla XR-treated pediatric patients. Pediatric patients who are not growing or gaining weight as expected may need to have their treatment interrupted
- Psoriatic Arthritis: Body weight loss of 5-10% was reported in 10% (49/497) of adult patients taking Otezla and in 3.3% (16/495) of patients taking placebo
- Behçet’s Disease: Body weight loss of >5% was reported in 4.9% (5/103) of patients taking Otezla and in 3.9% (4/102) of patients taking placebo
Drug Interactions: Apremilast exposure was decreased when co-administered with rifampin, a strong CYP450 enzyme inducer; loss of Otezla/Otezla XR efficacy may occur. Concomitant use of Otezla/Otezla XR with CYP450 enzyme inducers (e.g., rifampin, phenobarbital, carbamazepine, phenytoin) is not recommended

Adverse Reactions

Plaque Psoriasis: The most common adverse reactions (≥5%) are diarrhea, nausea, upper respiratory tract infection, and headache, including tension headache. Overall, the safety profile of Otezla in adult patients with mild to moderate plaque psoriasis and pediatric patients with moderate to severe plaque psoriasis was consistent with the safety profile established in adult patients with moderate to severe plaque psoriasis
Psoriatic Arthritis: The most common adverse reactions (≥5%) are diarrhea, nausea, and headache
Behçet’s Disease: The most common adverse reactions (≥10%) are diarrhea, nausea, headache, and upper respiratory tract infection

Use in Specific Populations

Advise pregnant women of the potential risk of fetal loss

INDICATIONS

Otezla/Otezla XR is indicated for the treatment of adult patients with plaque psoriasis who are candidates for phototherapy or systemic therapy
Otezla is indicated for the treatment of pediatric patients 6 years of age and older and weighing at least 20 kg with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy
Otezla XR is indicated for the treatment of pediatric patients 6 years of age and older and weighing at least 50 kg with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy
Otezla is indicated for the treatment of adult patients and pediatric patients 6 years of age and older and weighing at least 20 kg with active psoriatic arthritis
Otezla XR is indicated for the treatment of adult patients and pediatric patients 6 years of age and older and weighing at least 50 kg with active psoriatic arthritis
Otezla/Otezla XR is indicated for the treatment of adult patients with oral ulcers associated with Behçet’s Disease

Please click here for the full Prescribing Information.

References: 1. Otezla [package insert]. Thousand Oaks, CA: Amgen Inc. 2. Data on file, Amgen Inc. 3. Wells AF, Edwards CJ, Kivitz AJ, et al. Rheumatology (Oxford). 2018;57(7):1253-1263.

Study Design

Study Design

How Otezla Works

Dosing

Otezla has an established safety profile with no initial or ongoing lab monitoring 1

PALACE 1-3: ADVERSE REACTIONS THROUGH WEEK 16

AN ESTABLISHED SAFETY PROFILE THROUGH WEEK 16 1

PALACE 1-3: Adverse reactions reported in ≥2% of patients on Otezla 30 mg BID and ≥1% observed in patients on placebo for up to day 112 (week 16) 1,*

Discontinuation rates due to adverse reactions in the 3 trials 1:

5-Year Safety Data Video

THE MAJORITY OF PATIENTS REPORTING THE MOST COMMON ADVERSE REACTIONS OCCURRED WITHIN THE FIRST 2 WEEKS OF TREATMENT AND TENDED TO RESOLVE OVER TIME WITH CONTINUED DOSING 1

PALACE 4: ADVERSE REACTIONS THROUGH WEEK 16

AN ESTABLISHED SAFETY PROFILE IN DMARD-NAÏVE PATIENTS THROUGH WEEK 16 2

PALACE 4: Adverse reactions reported in ≥ 5% of patients through week 16 2,§

PALACE 4 Data Video

IMPORTANT SAFETY INFORMATION

IMPORTANT SAFETY INFORMATION

INDICATIONS

Otezla has an established safety profile with no initial or ongoing lab monitoring ¹

AN ESTABLISHED SAFETY PROFILE THROUGH WEEK 16 ¹

PALACE 1-3: Adverse reactions reported in ≥2% of patients on Otezla 30 mg
BID and ≥1% observed in patients on placebo for up to day 112 (week 16) ^1,*

Discontinuation rates due to adverse reactions in the 3 trials ¹:

THE MAJORITY OF PATIENTS REPORTING THE MOST COMMON ADVERSE REACTIONS OCCURRED WITHIN THE FIRST
2 WEEKS OF TREATMENT AND TENDED TO RESOLVE OVER TIME WITH CONTINUED DOSING ¹

AN ESTABLISHED SAFETY PROFILE IN
DMARD-NAÏVE PATIENTS THROUGH WEEK 16 ²

PALACE 4: Adverse reactions reported in ≥ 5% of patients through week 16 ^2,§